Physician profile
Alexandra Kaiser
NPI 1811287568
$559.18
in general payments reported to CMS, 2019-2025
12 companies · $134 in 2025
The $134 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $316 · 2022: $46.95 · 2023: $57.23 · 2024: $4.51 · 2025: $134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $195.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $246.75 | 2021 | |
| Celgene Corporation | $84.05 | 2021-2023 | Reblozyl |
| Daiichi Sankyo INC. | $49.23 | 2025 | Vanflyta |
| Takeda Pharmaceuticals U.S.A., INC. | $33.93 | 2025 | Iclusig |
| Astellas Pharma US INC | $31.31 | 2025 | Cresemba |
| Servier Pharmaceuticals LLC | $24.25 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $22.54 | 2023 | Imbruvica |
| Karyopharm Therapeutics INC. | $20.32 | 2021 | |
| Sobi, INC | $19.59 | 2025 | |
| Abbvie INC. | $17.64 | 2022 | |
| Janssen Biotech, INC. | $5.06 | 2022 | |
| Iovance Biotherapeutics, INC. | $4.51 | 2024 | Amtagvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexandra Kaiser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.